epirubicin + cyclophosphamide + docetaxel

epirubicin + cyclophosphamide + docetaxel is a sequential combination chemotherapy regimen utilized primarily in the neoadjuvant and adjuvant treatment of breast cancer. The regimen, often abbreviated as EC-T, involves an initial phase of the anthracycline epirubicin and the alkylating agent cyclophosphamide (EC), followed by a subsequent phase of the taxane docetaxel (T). Epirubicin exerts its cytotoxic effects through DNA intercalation and the inhibition of DNA topoisomerase II alpha, leading to DNA strand breaks. Cyclophosphamide is a nitrogen mustard alkylating agent that forms DNA cross-links, thereby inhibiting DNA replication and transcription. Docetaxel binds to and stabilizes microtubules, preventing their disassembly and resulting in cell cycle arrest at the G2/M phase. This specific regimen is being evaluated by Zhejiang Provincial People's Hospital in clinical studies to determine its efficacy and safety, particularly when combined with adjunctive therapies like traditional Chinese medicine.

Other names

epirubicin, cyclophosphamide, and docetaxelEC followed by docetaxelEC followed by T